Ozempic NAION Vision Loss Risks Confirmed in Another Study
Findings are similar to those discovered by Harvard researchers in an Ozempic vision loss study published last summer.
Findings are similar to those discovered by Harvard researchers in an Ozempic vision loss study published last summer.
With the first Ozempic lawsuit bellwether trials not expected to begin until at least late 2026 or early 2027, the court will address motions to dismiss and other “cross cutting” issues in 2025.
Lawsuit claims Novo Nordisk's failures to warn about the risk of gastroparesis and Ileus from Ozempic were "wanton, willful, fraudulent, reckless acts."
Tests found Ozempic caused the hearts of mice to atrophy, leaving researchers unsure whether the loss of cardiac muscle mass may occur in humans as well.
The Court may soon allow future lawsuits over Ozempic, Wegovy, Mounjaro and other GLP-1s to be brought using a Short Form Complaint, adopting allegations from the MDL Master Complaint.
Researchers warn that it is "vital" to reduce PFAS exposure for expecting mothers, given long-term health risks for unborn children.
New GLP-1 warnings will urge users to inform their doctors before surgery if they are taking the diabetes and weight loss drugs.
Court will examine general causation, along with other “cross cutting” issues, before selecting any individual Ozempic gastroparesis lawsuits for trial workup.
Research indicates women have seen an increased risk of heart disease, stroke and type 2 diabetes in recent decades, correlating with an increased use of birth control pills.
Lawsuit indicates that the gastroparesis diagnosis from Ozempic was confirmed after plaintiff underwent a gastric emptying test, which is evidence not present in many other claims in the litigation.